statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INOVIO Reports Inducement Grants Under Inducement Plan INOVIO Reports Inducement Grants Under Inducement Plan PR Newswire PLYMOUTH MEETING, Pa., May 1, 2024 PLYMOUTH MEETING, Pa., May 1, 2024...

INOVIO Reports Inducement Grants Under Inducement Plan

INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024 INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024 PR Newswire PLYMOUTH MEETING, Pa., April 29, 2024 PLYMOUTH...

INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024

INOVIO to Participate in Upcoming Investor Conferences in May INOVIO to Participate in Upcoming Investor Conferences in May PR Newswire PLYMOUTH MEETING, Pa., April 29, 2024 PLYMOUTH MEETING, Pa...

INOVIO to Participate in Upcoming Investor Conferences in May

INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of...

INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

StockNews.com downgraded shares of Inovio Pharmaceuticals (NASDAQ:INO - Free Report) from a hold rating to a sell rating in a report released on Friday morning.
Several other research analysts have...

Inovio Pharmaceuticals (NASDAQ:INO) Downgraded to Sell at StockNews.com

Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) was the target of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling...

Short Interest in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Expands By 10.8%

Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on Inovio Pharmaceuticals (INO Research Report), retaining the price target of $18...

Inovio Pharmaceuticals: A Strong Buy on Promising IL-12 Therapy Developments and Market Interest

This price move could be a signal that INO may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Inovio Pharmaceuticals (INO, $12.99) price may drop as it broke higher Bollinger Band on Mar 27, 2024

INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine PR Newswire PLYMOUTH MEETING...

INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine

This is a signal that INO's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Inovio Pharmaceuticals (INO, $12.4) RSI Indicator left the overbought zone on March 25, 2024

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Watchers	93,557
52-Wk Low	$3.89
52-Wk High	$14.75

Volume	228,244.00
52-Wk High	$14.75
52-Wk Low	$3.89

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.99	--	--	N/A
Q4'23	-$1.19	-$1.10	7.25%	BEAT
Q3'23	-$0.13	-$1.56	-1131.58%	MISSED
Q2'23	-$0.15	-$0.13	10.34%	BEAT
Q1'23	-$0.15	-$0.16	-10.34%	MISSED

INO Inovio Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals